Axsome Therapeutics Past Earnings Performance
Past criteria checks 0/6
Axsome Therapeutics's earnings have been declining at an average annual rate of -30.2%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 92.2% per year.
Key information
-30.2%
Earnings growth rate
-23.9%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 92.2% |
Return on equity | -125.3% |
Net Margin | -88.4% |
Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Axsome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 271 | -239 | 323 | 98 |
30 Sep 23 | 223 | -202 | 297 | 82 |
30 Jun 23 | 182 | -184 | 255 | 68 |
31 Mar 23 | 145 | -159 | 207 | 63 |
31 Dec 22 | 50 | -187 | 159 | 58 |
30 Sep 22 | 26 | -160 | 117 | 57 |
30 Jun 22 | 9 | -150 | 96 | 55 |
31 Mar 22 | 0 | -141 | 81 | 54 |
31 Dec 21 | 0 | -130 | 67 | 58 |
30 Sep 21 | 0 | -126 | 58 | 62 |
30 Jun 21 | 0 | -114 | 44 | 63 |
31 Mar 21 | 0 | -100 | 35 | 59 |
31 Dec 20 | 0 | -103 | 29 | 70 |
30 Sep 20 | 0 | -99 | 24 | 62 |
30 Jun 20 | 0 | -95 | 21 | 63 |
31 Mar 20 | 0 | -90 | 16 | 63 |
31 Dec 19 | 0 | -68 | 14 | 54 |
30 Sep 19 | 0 | -53 | 11 | 41 |
30 Jun 19 | 0 | -42 | 10 | 32 |
31 Mar 19 | 0 | -37 | 10 | 26 |
31 Dec 18 | 0 | -31 | 9 | 23 |
30 Sep 18 | 0 | -29 | 9 | 21 |
30 Jun 18 | 0 | -27 | 9 | 19 |
31 Mar 18 | 0 | -26 | 8 | 19 |
31 Dec 17 | 0 | -29 | 7 | 20 |
30 Sep 17 | 0 | -29 | 7 | 21 |
30 Jun 17 | 0 | -30 | 7 | 22 |
31 Mar 17 | 0 | -29 | 7 | 22 |
31 Dec 16 | 0 | -27 | 6 | 21 |
30 Sep 16 | 0 | -23 | 5 | 18 |
30 Jun 16 | 0 | -21 | 4 | 14 |
31 Mar 16 | 0 | -16 | 3 | 10 |
31 Dec 15 | 0 | -12 | 2 | 7 |
30 Sep 15 | 0 | -10 | 2 | 6 |
30 Jun 15 | 0 | -6 | 2 | 6 |
31 Mar 15 | 0 | -6 | 2 | 5 |
31 Dec 14 | 0 | -6 | 1 | 4 |
Quality Earnings: 0HKF is currently unprofitable.
Growing Profit Margin: 0HKF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0HKF is unprofitable, and losses have increased over the past 5 years at a rate of 30.2% per year.
Accelerating Growth: Unable to compare 0HKF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0HKF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 0HKF has a negative Return on Equity (-125.27%), as it is currently unprofitable.